CFDE Data Portal | Search ADAMTS7P4

	Label	Description
	ADAMTS7P4 Gene (Entity type)	ENSG00000218052 - ADAMTS7 pseudogene 4
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 5 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 11 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE81796 enzalutamide LNCaP C4-2 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE131660 piperlongumine 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE183741 GSE183806 POU2F2 POU2AF1 knockdown UtE-iPS-1 6 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE213845 EZH2 inhibition 3 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS

ADAMTS7P4

ENSG00000218052 - ADAMTS7 pseudogene 4

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human up

A Gene Set from LINCS

GSE113655 phenol 5 v 4 human dn

A Gene Set from LINCS

GSE239844 crizotinib 11 v 2 human up

A Gene Set from LINCS

GSE81796 enzalutamide LNCaP C4-2 0 v 1 human up

A Gene Set from LINCS

GSE162892 ISOX 3 v 1 human up

A Gene Set from LINCS

GSE131660 piperlongumine 2 v 0 human dn

A Gene Set from LINCS

GSE183741 GSE183806 POU2F2 POU2AF1 knockdown UtE-iPS-1 6 v 4 human dn

A Gene Set from LINCS

GSE213845 EZH2 inhibition 3 v 5 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.